| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f33c4f62ed733d0a05163acf8424eb6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-28 |
| filingDate |
2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43f63241422ec0b6d70e196243c91ec8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8e80c22f123d4b4b298b1985d1f530b |
| publicationDate |
2008-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008133305-A |
| titleOfInvention |
Drugs that enhance the inhibitory action of endothelial cells |
| abstract |
The use of human erythropoietin (EPO) for the purpose of enhancing endothelial injury caused by chemotherapeutic agents and / or inhibition of endothelial growth is described. The combination of chemotherapeutic agent and EPO will be described. An agent for treating an angiogenic solid tumor in a patient in need of treatment, said agent comprising an endothelial inhibitory amount of erythropoietin and administered in combination with an antitumor chemotherapeutic agent A drug having an endothelial inhibition amount of erythropoietin of 750 to 2000 units / kg [Selection figure] None |
| priorityDate |
1996-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |